-
Innovation Ranking
Innovation Ranking – Surface Oncology Inc
Surface Oncology Inc (Surface Oncology) is an immuno-oncology company. It develops novel antibody therapies for the treatment of cancer. The company’s product portfolio includes SRF388, to treat various diseases like renal cell carcinoma, hepatocellular carcinoma, and non-small-cell lung cancer; SRF617, to treat various tumors like gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology also provides SRF114, NZV930 and GSK4381562 antibodies. It also carries out research and development activities and pre-clinical studies. The company has entered two...
-
Analyst Opinions
Development of Electric Mining Vehicles in Surface and Underground Mining, 2024
As miners strive to reduce greenhouse gas emissions, many are beginning to invest in battery-powered and electric-powered mining fleets as they embark on the long-term goal of diesel displacement. 'The pace of switching to electric mining vehicles is increasing. Underground over 320 LHDs and mining trucks were running on electric power by March 2024, while for surface mines the use of electric-powered mining trucks has been picking up with almost 240 trolley-assist trucks and 129 battery-powered surface trucks.
-
Product Insights
Leukocyte Surface Antigen CD47 – Drugs In Development, 2023
Global Markets Direct’s Leukocyte Surface Antigen CD47 provides in depth analysis on Leukocyte Surface Antigen CD47 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukocyte Surface Antigen...
-
Product Insights
T Cell Surface Glycoprotein CD4 – Drugs In Development, 2023
Global Markets Direct’s T Cell Surface Glycoprotein CD4 provides in depth analysis on T Cell Surface Glycoprotein CD4 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T...
-
Product Insights
T Cell Specific Surface Glycoprotein CD28 – Drugs In Development, 2023
Global Markets Direct’s T Cell Specific Surface Glycoprotein CD28 provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Plasmodium falciparum Merozoite Surface Protein 1 – Drugs In Development, 2023
Global Markets Direct’s Plasmodium falciparum Merozoite Surface Protein 1 provides in depth analysis on Plasmodium falciparum Merozoite Surface Protein 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Cell Surface Glycoprotein CD200 Receptor 1 – Drugs In Development, 2023
Global Markets Direct’s Cell Surface Glycoprotein CD200 Receptor 1 provides in depth analysis on Cell Surface Glycoprotein CD200 Receptor 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
T Cell Surface Glycoprotein CD3 Epsilon Chain – Drugs In Development, 2023
Global Markets Direct’s T Cell Surface Glycoprotein CD3 Epsilon Chain provides in depth analysis on T Cell Surface Glycoprotein CD3 Epsilon Chain targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Analyst Opinions
Surface Mining Equipment Market Analysis by Region, Population, Commodity and Forecast to 2030
Explore the following trends and analysis from our ‘Surface Mining Equipment’ market report: Understand the breakdown of equipment counts by region (Asia Pacific, Australasia, Europe, Former Soviet Union, Middle East & Africa, North America, and South & Central America). Analyze the major mining countries such as Australia, Canada, Chile, China, India, Indonesia, Peru, Russia, South Africa, and the US. Assess the total population by commodity to set smart business goals. Learn the market shares of the leading OEMs by type of...
-
Sector Analysis
NewRomania Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Romania Defense Market Report Overview In 2024, Romania's defense budget is worth $8.6 billion. The country’s defense budget will grow at a CAGR of more than 2% during 2025-2029. Defense industry development is one of the prominent factors leading to the growth of the market. Romania Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for More Insights into the Romania Defense Market Forecast Download a Free Report Sample The Romania defense market research report provides the market size...